Dutch pharmaceutical giant Norgine has inaugurated new offices in Wettenberg, Germany, marking a significant step in its ongoing growth strategy. This move strengthens its commitment to its largest product sales market, where it has been a key player since 1928. The new facility is set to enhance the company’s operations and support services, ensuring the […]
Vyriad, a US-based biotech company, has partnered with Germany’s Merck to initiate a Phase 1 clinical trial targeting metastatic colorectal cancer. This trial explores the combined potential of Vyriad’s Voyager-V1 and Merck’s Bavencio (avelumab), offering a new approach to immuno-oncology treatment. Voyager-V1, developed by Vyriad, is an oncolytic virotherapy employing a bullet-shaped, negative-sense RNA virus […]
Strategic Expansion in Cancer Treatment: Eli Lilly and Company (Lilly), a leading US pharmaceutical firm, has finalized its acquisition of Armo BioSciences, a California-based immuno-oncology company, for $1.6 billion. This move is part of Lilly’s strategic initiative to enhance its immuno-oncology program, one of the most promising areas in cancer research today. Details of the […]
Cancer is one of the deadliest diseases affecting the human and animals, caused due to uncontrolled cell growth with a nature to spread rapidly to several organs. In this post let us know in detail on how to prevent cancer with naturally available foods and also on what is cancer, cancer causes, cancer symptoms and […]
Significant Acquisition in Pharma Industry: US pharmaceutical giant Merck has announced a definitive agreement to acquire Viralytics, an Australian biotech company, for AUD 502 million (approximately $394 million). This acquisition is set to significantly enhance Merck’s portfolio in the burgeoning field of immuno-oncology. Strategic Expansion of Immuno-Oncology Pipeline: Through this acquisition, Merck aims to expand […]
Seattle Genetics, a leader in oncology biotechnology, has announced the acquisition of Cascadian Therapeutics for approximately $614 million, a strategic move to enhance its portfolio of solid tumor treatments. The acquisition, which involves Seattle Genetics paying $10 per share in cash for the California-based company, is set to significantly advance its research in cancer therapies, […]
Roche Pharmaceuticals, a prominent Swiss pharmaceutical company, has entered into a definitive merger agreement to acquire Ignyta, a U.S. cancer drug maker, for $1.7 billion in an all-cash transaction. This acquisition, priced at $27 per share, significantly bolsters Roche’s oncology portfolio by adding advanced gene therapy-based cancer drugs that are in the early stages of […]
Lilly gastric cancer drug Cyramza (ramucirumab) did meet the primary endpoint of a phase 3 trial RAINFALL but could not improve overall survival of patients.
In a recent announcement, Eli Lilly and Company disclosed that its phase 3 RAINFALL trial of the drug Cyramza (ramucirumab) for the treatment of HER2-negative metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma achieved mixed results. While the trial met its primary endpoint of progression-free survival (PFS), it did not improve overall survival (OS), a key […]
Report on AstraZeneca blood cancer drug Calquence or acalabrutinib FDA approval for mantle cell lymphoma treatment in adult patients who had at least one prior therapy.
AstraZeneca has achieved a significant milestone with the early FDA approval of Calquence (acalabrutinib) for the treatment of adult patients with mantle cell lymphoma who have undergone at least one prior therapy. This announcement, made by the U.S. Food and Drug Administration on Tuesday, marks a crucial development in the treatment of this aggressive form […]
The Indian FDA (CDSCO - Central Drugs Standard Control Organization) has granted a commercial license to APAC Biotech to market Apceden, a Dendritic cell-based autologous Immuno-oncology drug for prostate, ovarian, colo-rectal and non small cell lung carcinoma form of cancers.
The Central Drugs Standard Control Organization (CDSCO), India’s regulatory authority, has granted a commercial license to APAC Biotech for the marketing of Apceden, a Dendritic cell-based autologous immuno-oncology drug. This approval marks a significant advancement in the treatment of various cancer types, including prostate, ovarian, colorectal, and non-small cell lung carcinoma. Pioneering Cancer Therapy Approved […]